Tests INCA033989 Against Standard Care in Essential Thrombocythemia
Tests INCA033989 against standard treatment in adults with essential thrombocythemia and a CALR mutation.
Plain-language title generated from the registry record
Registry title: A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Key facts
- Where
- Alicante, Barcelona, Bilbao, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Palma, Salamanca, Santiago de Compostela, Valencia, and Zaragoza, SpainSee the 15 sites
- Phase
- Phase 3
Where in Spain
- Hospital General Unviersitario de AlicanteAlicante, SpainNot yet recruiting
- Hospital Clinic de Barcelona (Hospital Clinic i Provincial)Barcelona, SpainNot yet recruiting
- Hospital Universitario Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital Universitario de BasurtoBilbao, SpainNot yet recruiting
- Instituto Catalan de Oncologia Hospital Duran i ReynalsL'Hospitalet de Llobregat, SpainNot yet recruiting
- Hospital Universitario de Gran Canaria Doctor NegrínLas Palmas de Gran Canaria, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario Ramón y CajalMadrid, SpainNot yet recruiting
- Puerta de Hierro Majadahonda University HospitalMajadahonda, SpainNot yet recruiting
- Hospital Universitario Virgen de la VictoriaMálaga, SpainNot yet recruiting
- Hospital Universitari Son EspasesPalma, SpainNot yet recruiting
- Hospital Clinico Universitario de SalamancaSalamanca, SpainNot yet recruiting
- Hospital Clínico Universitario de Santiago de CompostelaSantiago de Compostela, SpainNot yet recruiting
- Hospital Universitario Doctor PesetValencia, SpainNot yet recruiting
- Hospital Universitario Miguel Servet (Hospital Infantil)Zaragoza, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07623200EU 2026-525398-38-00
- Record updated
- 5 November 2026
- Original description
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.Read full original descriptionShow less
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Inclusion: Confirmed diagnosis of high-risk ET; Presence of mutCALR; Prior treatment with at least 1 cytoreductive therapy.
Exclusion: Major bleeding or thrombosis within the last 3 months prior to study enrollment; Any prior allogenic or autologous stem-cell transplantation; Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy; Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease; Other protocol-defined Inclusion/Exclusion Criteria apply; Presence of any hematologic malignancy other than ET.